Global race for better leukemia treatment for the elderly
NCT ID NCT06389292
Summary
This large, late-stage trial is testing whether adding a new oral drug called APG-2575 (lisaftoclax) to a standard treatment (azacitidine) helps older adults with newly diagnosed acute myeloid leukemia (AML) live longer. The study will enroll about 486 patients worldwide who are not eligible for intensive chemotherapy. Participants are randomly assigned to receive either the new drug combination or the standard treatment plus a placebo pill to see which is more effective and safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Botkin Moscow Multidisciplinary Research and Clinical Center
RECRUITINGMoscow, 125284, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hematology Hospital of the Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Leningrad Regional Clinical Hospital
RECRUITINGSaint Petersburg, 194291, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Moscow Multidisciplinary Clinical Center "Kommunarka"
RECRUITINGMoscow, 108814, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Russian Research Institute of Hematology and Transfusiology of the Federal Medical and Biological Agency
RECRUITINGSaint Petersburg, 191024, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310003, China
Contact Phone: •••-•••-••••
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.